Compare Gilead Sciences, Inc. (GILD) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Newegg Commerce Inc — how do they compare? Gilead Sciences, Inc. trades at $151.27 (market cap $182.40B), while Newegg Commerce Inc trades at $11.69 (market cap $243.30M). The key difference: Gilead Sciences, Inc. is far larger — about 749.7× Newegg Commerce Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Newegg Commerce Inc for 14 Days on average.
| GILD | NEGG | |
|---|---|---|
Market Cap | $182.40B | $243.30M |
Volume | 4,469,821 | 41,252 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $92.74 |
52-Week Low | $116.74 | $11.49 |
Typical Hold Time | 111 Days | 14 Days |
Enterprise Value | $205.46B | $213.53M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
NEGG stock trades at $12.01, up 0.84% today, but technical indicators are bearish with moving averages signaling a downtrend. The company shows improving fundamentals, with revenue of $1.44B in 2025 and a net income margin turning positive to 0.68% in 2026 projections. Recent news highlights partnerships with Western Digital and Hewlett Packard Enterprise to support IT infrastructure, though insider selling has created negative sentiment.
The outlook is mixed; earnings beats and margin improvement offer upside, but the stock faces bearish technicals and a consensus price target of $7.75 below the current price. Key risks include volatile cash flows and high liabilities, while a single analyst rates it Buy. Investors should weigh operational progress against valuation concerns and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
